Dr. Murthy is a veteran molecular biologist and biochemist, with more than 25 years experience in academia and the pharmaceutical industry. Among his scientific accomplishments, he reported in Nature the discovery, purification, characterization, cloning, and expression of novel RNA binding proteins from complex mixtures of cellular extracts.
In his previous position as Director of Biology at Inotek Pharmaceuticals Corporation, Dr. Murthy produced and patented novel broad-spectrum anti-flagellin human monoclonal antibodies, and led the Company’s poly (ADP-ribose) polymerase biology program, culminating in a multi-hundred million dollar strategic partnership with Genentech. In addition, Dr. Murthy led Inotek’s pharmacology and biology programs in Adenosine 1, 2a, and 3 receptor technology, built its purinergic small molecule program in inosine biology, and supervised the discovery work that formed the basis of its nitric oxide synthase inhibitor, xanthine oxidase inhibitor, and peroxynitrite decomposition catalyst programs. His research efforts formed the basis for more than ten clinical programs at Inotek Pharmaceuticals. Dr. Murthy joined Radikal Therapeutics in 2010 as Senior Director of Biology and currently leads its molecular and cell biology programs.